Literature DB >> 7499965

An analogue of lipid A and LPS from Rhodobacter sphaeroides inhibits neutrophil responses to LPS by blocking receptor recognition of LPS and by depleting LPS-binding protein in plasma.

Y Aida1, K Kusumoto, K Nakatomi, H Takada, M J Pabst, K Maeda.   

Abstract

When incubated with lipopolysaccharide (LPS) in the presence of plasma, neutrophils become primed for enhanced release of superoxide in response to triggering by formyl-Met-Leu-Phe (fMLP). The effect of LPS on phagocytes is inhibited by a synthetic lipid A precursor, LA-14-PP (lipid IVa) or by LPS from Rhodobacter sphaeroides (Rs). We studied the mechanisms by which LA-14-PP or Rs-LPS inhibited LPS-induced responses. When neutrophils were exposed to LA-14-PP or Rs-LPS for 3 min and then to Escherichia coli-LPS, the antagonists inhibited priming for superoxide release, and also blocked up-regulation of CD11b and adherence. This inhibition was dependent on plasma, was not overcome by higher amounts of E. coli-LPS or plasma, and was not observed at 0 degrees C, suggesting that E. coli-LPS was not able to interact with its receptor or other cellular recognition molecule in neutrophils that had been exposed to the antagonists. The alternative possibility that LA-14-PP or Rs-LPS depleted a plasma cofactor, resulting in inhibition of priming, was investigated by using LPS from Porphyromonas gingivalis (Pg) and Bordetella pertussis (Bp). These LPS primed neutrophils in a plasma-dependent and CD14-dependent manner, but were not blocked by LA-14-PP or Rs-LPS. When sub-optimal concentrations of plasma were exposed to LA-14-PP or Rs-LPS, and then mixed with Pg-LPS or Bp-LPS, followed by incubation with neutrophils, priming and up-regulation of CD11b were inhibited, and this inhibition was overcome by increasing the concentration of plasma. Binding of LPS-binding protein (LBP) in plasma to immobilized E. coli-LPS was inhibited by pre-incubation of plasma with LA-14-PP or Rs-LPS. Together with the result that treatment of plasma with anti-LBP antibody abolished the cofactor activity of plasma, these results indicated that LA-14-PP and Rs-LPS depleted LBP from plasma, resulting in inability of LPS to act on neutrophils. Thus LA-14-PP and Rs-LPS inhibited the action of LPS on neutrophils by at least two mechanisms, blocking of LPS receptor recognition and depletion of the cofactor LBP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499965     DOI: 10.1002/jlb.58.6.675

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  15 in total

1.  Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia.

Authors:  J E Hughes; J Stewart; G R Barclay; J R Govan
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

2.  High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products.

Authors:  Andréy Mazarati; Mattia Maroso; Valentina Iori; Annamaria Vezzani; Mirjana Carli
Journal:  Exp Neurol       Date:  2011-08-22       Impact factor: 5.330

3.  C2-ceramide and C6-ceramide inhibited priming for enhanced release of superoxide in monocytes, but had no effect on the killing of leukaemic cells by monocytes.

Authors:  Y Nakabo; M J Pabst
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

4.  Lipopolysaccharide and its analog antagonists display differential serum factor dependencies for induction of cytokine genes in murine macrophages.

Authors:  P Y Perera; N Qureshi; W J Christ; P Stütz; S N Vogel
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

5.  Mechanisms of the Macrolide-Induced Inhibition of Superoxide Generation by Neutrophils.

Authors:  Kohji Nozoe; Yoshitomi Aida; Takao Fukuda; Terukazu Sanui; Fusanori Nishimura
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

6.  Diphosphoryl lipid A from Rhodobacter sphaeroides inhibits complexes that form in vitro between lipopolysaccharide (LPS)-binding protein, soluble CD14, and spectrally pure LPS.

Authors:  B W Jarvis; H Lichenstein; N Qureshi
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

7.  Lipoteichoic acid acts as an antagonist and an agonist of lipopolysaccharide on human gingival fibroblasts and monocytes in a CD14-dependent manner.

Authors:  S Sugawara; R Arakaki; H Rikiishi; H Takada
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

8.  TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes.

Authors:  Zhongyang Lu; Xiaoming Zhang; Yanchun Li; Maria F Lopes-Virella; Yan Huang
Journal:  Immunobiology       Date:  2015-06-30       Impact factor: 3.144

9.  Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages.

Authors:  M Hirschfeld; J J Weis; V Toshchakov; C A Salkowski; M J Cody; D C Ward; N Qureshi; S M Michalek; S N Vogel
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

10.  Oral intake of lipopolysaccharide regulates toll-like receptor 4-dependent granulopoiesis.

Authors:  Melanie Märklin; Stefanie Bugl; Stefan Wirths; Julia-Stefanie Frick; Martin R Müller; Hans-Georg Kopp; Dominik Schneidawind
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.